Carbon monoxide releasing molecule-2 inhibits pancreatic stellate cell proliferation by activating p38 MAPK/ HO-1 signaling

Christian I. Schwer, Manuel Mutschler, Patrick Stoll, Ulrich Goebel, Matjaz Humar, Alexander Hoetzel, and Rene Schmidt

Department of Anesthesiology, University Medical Center, Freiburg, Germany

Running title: CORM-2 inhibits pancreatic stellate cell proliferation

Address for correspondence:

Rene Schmidt, M.D., Department of Anesthesiology, University Medical Center, Hugstetter Strasse 55, D-79106 Freiburg, Germany; Phone: (+49) 761 2702306, Fax: (+49) 761 2702396, E-mail: rene.schmidt@uniklinik-freiburg.de

Number of text pages: 30

Number of figures: 10

Number of references: 39

Number of words in the *Abstract*: 248

Number of words in the *Introduction*: 520

Number of words in the *Discussion*: 1231

Abbreviations: ANOVA, analysis of variance; BrdU, 5-bromo-2′-deoxyuridine; Cdk, cyclin-dependent kinase; CORM-2, tricarbonyldichlororuthenium(II) dimer; ERK, extracellular signal-regulated kinase; FCS, fetal calf serum; GAPDH, glyceraldehyde 3-phosphate dehydrogenase; HO-1, heme oxygenase-1; IMDM, Iscove′s modified Dulbecco′s medium; JNK, c-Jun NH_2-terminal kinase; MAP kinase, mitogen-activated protein kinase; PSC, pancreatic stellate cell; SB203580, 4-(4-flurophenyl)-2-(4-methylsulfinylphenyl)-5-(4-pyridyl)imidazole; SEM, standard error of the mean; siRNA, small interfering RNA; SnPP, tin protoporphyrin IX

ABSTRACT

Proliferation of pancreatic stellate cells (PSCs) plays a cardinal role during fibrosis development. Therefore, the suppression of PSC growth represents a therapeutic option for the treatment of pancreatic fibrosis. It has been shown that up-regulation of the enzyme heme oxygenase-1 (HO-1) could exert anti-proliferative effects on PSCs, but no information is available on the possible role of carbon monoxide (CO), a catalytic by-product of the HO metabolism, in this process. In the present study, we have examined the effect of CO releasing molecule-2 (CORM-2) liberated CO on PSC proliferation and have elucidated the mechanisms involved. Using primary rat PSCs, we found that CORM-2 inhibited PSC proliferation at non-toxic concentrations by arresting cells at the G_0/G_1 phase of the cell cycle. This effect was associated with activation of p38 mitogen-activated protein kinase (MAPK) signaling, induction of HO-1 protein and up-regulation of the cell cycle inhibitor p21$^{Waf1/Cip1}$. The p38 MAPK inhibitor SB203580 abolished the inhibitory effect of CORM-2 on PSC proliferation and prevented both CORM-2-induced HO-1 and p21$^{Waf1/Cip1}$ up-regulation. Treatment with tin protoporphyrin IX, an HO inhibitor, or transfection of HO-1 small interfering RNA abolished the inductive effect of CORM-2 on p21$^{Waf1/Cip1}$ and reversed the suppressive effect of CORM-2 on PSC growth. The ability of CORM-2 to induce cell cycle arrest was abrogated in p21$^{Waf1/Cip1}$ silenced cells. Taken together, our results suggest that CORM-2 inhibits PSC proliferation by activation of the p38/ HO-1 pathway. These findings may indicate a therapeutic potential of CO carriers in the treatment of pancreatic fibrosis.

Chronic pancreatitis (CP) is a progressive fibroinflammatory disease that, in its end stages, results in loss of organ architecture and functional insufficiency of the gland (Witt et al., 2007). Therapeutic options are rare and treatment modalities focus on improvement of the patient´s quality of life. With the identification, isolation, and characterization of the pancreatic stellate cell (PSC) (Apte et al., 1998; Bachem et al., 1998), a considerable knowledge has been gained about the pathogenesis of this disease, particularly related to the mechanisms responsible for the development of pancreatic fibrosis, a dominant feature of CP (Apte and Wilson, 2004). In the normal pancreas, PSCs are quiescent and show a similar morphology to hepatic stellate cells, the principal effector cells in liver fibrosis (Friedman, 1993; Bachem et al., 1998). When activated by toxic stimuli such as ethanol or by cytokines, PSCs undergo a transition into highly proliferative myofibroblast-like cells (Haber et al., 1999). Activated PSCs express the cytoskeletal protein α-smooth muscle actin and regulate both synthesis and degradation of the extracellular matrix components that comprise fibrous tissue (Apte and Wilson, 2004). Taking this into account, compounds that inhibit PSC proliferation or induce apoptosis in activated PSCs may have the potential to become a new approach for the treatment of pancreatic fibrosis (Omary et al., 2007).

Carbon monoxide (CO) has shown promising potential as therapeutic agent in animal models of lung fibrosis (Zhou et al., 2005; Zheng et al., 2008), despite its limitations as a toxic gas and environmental hazard. Endogenous CO arises principally as the by-product of heme catabolism, by action of heme oxygenase (HO) enzymes (Tenhunen et al., 1968). In recent years, the physiological importance of CO as a gaseous mediator of many biological and cellular processes has been realized (Maines, 1997; Taille et al., 2005). The effect of CO on cell proliferation is variable and seems to be cell-type specific. As an example, it has been reported that

exposure of cells to CO gas suppresses proliferation in airway smooth muscle cells (Song et al., 2002), vascular smooth muscle cells (Otterbein et al., 2003) and T lymphocytes (Song et al., 2004), whereas an increase in proliferation was observed in endothelial cells (Wegiel et al., 2008).

CO-releasing molecules (CORMs) are a group of metal carbonyl compounds capable of delivering defined amounts of CO into cellular systems, thereby reproducing the biological effects of CO derived from HO activity (Motterlini et al., 2002; Sawle et al., 2006). CORMs have shown anti-proliferative effects in airway smooth muscle cells (Taille et al., 2005). Previous observations from our laboratory suggest an anti-fibrotic action of HO-1 in PSCs (Schwer et al., 2008) and several lines of evidence indicate that CO mediates many of the biological actions of HO-1 (Ryter et al., 2006).

We therefore tested the hypothesis that CO, liberated from CORM-2 (tricarbonyldichlororuthenium(II) dimer), may suppress PSC proliferation. The aims of this study were as follows: 1) to investigate whether CORM-2 affects PSC proliferation, 2) to characterize the effects of CORM-2 on cell cycle progression of PSCs, and 3) to explore the role of the MAPK pathways, HO-1 and the cell cycle inhibitor $p21^{Waf1/Cip1}$ under these experimental conditions.

MATERIALS AND METHODS

Reagents

Collagenase P and 5-bromo-2´-deoxyuridine (BrdU) cell proliferation kits were purchased from Roche Diagnostics (Mannheim, Germany). Iohexol (Nycodenz) was obtained from Nycomed (Oslo, Norway) and Hank´s buffered salt solution was from Invitrogen (Karlsruhe, Germany). Iscove´s modified Dulbecco´s medium (IMDM) and supplements for cell culture were obtained from Invitrogen. The polyclonal rabbit antibodies anti-phospho-p38, anti-total-p38, anti-phospho-ERK1/2, anti-total-ERK1/2, anti-phospho-JNK, anti-total-JNK, anti-phospho-MKK3/MKK6, anti-total-MKK3/MKK6 and anti-phospho-MAPKAPK-2 were obtained from Cell Signaling Technology (Danvers, MA, USA), and polyclonal rabbit anti HO-1 antibody was from Assay Designs (Ann Arbor, MI, USA). Monoclonal mouse anti-p21$^{Waf1/Cip1}$ antibody was purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA) and monoclonal mouse anti-glyceraldehyde 3-phosphate dehydrogenase (GAPDH) antibody was from Nventa Biopharmaceuticals (San Diego, CA, USA). Horseradish peroxidase-conjugated antibodies and the ECL kit were obtained from GE Healthcare (Little Chalfont, Buckinghamshire, UK). All other reagents were purchased from Sigma Chemie (Deisenhofen, Germany) unless indicated otherwise.

Isolation and Culture of PSCs

All animal procedures were performed in accordance with the Institute of Laboratory Animal Resources (1996). Rat PSCs were prepared from the pancreas of male Wistar rats (Charles River, Sulzfeld, Germany) weighting 250 to 300 g according to the procedure described by Shinji et al. (2002). In brief, the pancreas was digested with 0.03% collagenase P in Hank´s buffered salt solution. The resultant suspension of cells was centrifuged in a 13.2% iohexol gradient at 1400 g for 20 min. Stellate

cells separated into a fuzzy band just above the interface of the iohexol solution and the aqueous buffer. This band was harvested, and the cells were washed and resuspended in IMDM containing 10% fetal calf serum (FCS), 4 mM glutamine, and antibiotics (penicillin 100 U/ml, streptomycin 100 mg/ml). Cell purity was always more than 90% as assessed by vitamin A autofluorescence. After reaching confluency, cells were harvested and replated at equal seeding densities. All experiments were performed using culture-activated cells (passages 2 - 4). PSCs were incubated in serum-free medium for 24 hours before the addition of experimental reagents.

Treatment of Cells

The carbon monoxide releasing molecule tricarbonyldichlororuthenium(II) dimer (CORM-2; Sigma, Deisenhofen, Germany), the p38 MAPK inhibitor SB203580 (Calbiochem, Bad Soden, Germany) and the HO inhibitor tin protoporphyrin IX (SnPP; Frontier Scientific Europe, Carnforth, UK) were dissolved in dimethyl sulfoxide (DMSO) and then diluted in culture medium [0.1% (v/v)]. Control cells were treated with the same vehicle. Potential cytotoxic effects of the administered solutions were assessed by lactate dehydrogenase (LDH) release assays of the collected culture media.

Lactate Dehydrogenase Release Assay

Serum-starved PSCs were treated with CORM-2 at the indicated concentrations for 24 hours. LDH in conditioned media was determined as medium LDH. LDH in cell lysates was analyzed as cellular LDH. LDH in IMDM with 10% FCS was considered as contamination arising from FCS and subtracted from medium and cellular LDH. LDH activities were determined by an LDH assay kit (Roche Diagnostics, Mannheim, Germany) according to the manufacturer's instructions.

Fluorogenic Caspase Activity Assay

Total protein cell extracts of 5×10^6 cells per sample (10 µl) were mixed with 90 µl of assay buffer (100 mM HEPES, pH 7.5, 2 mM dithiothreitol, and 2 mM phenylmethylsulfonyl fluoride). The respective fluorogenic substrate for caspase-3 and -7, 7-amino-4-methylcoumarin (Ac-DEVD-AMC, 1 µl, 60 µM; Alexis Corporation, Gruenberg, Germany) was added and the fluorescence was measured at 30ºC for 30 min in a Microplate SpectraMax Gemini XS reader (Molecular Devices, Sunnyvale, CA, USA) at 380/460 nm.

Determination of Cell Growth

Cultured PSCs were passaged twice and replated at equal seeding densities into 24-well culture plates. After a 24-h serum deprivation, triplicate wells of cells were then exposed to CORM-2 (12.5 – 100 µM) for 30 min, followed by a 24-h stimulation with 10% FCS. Cells incubated in medium without FCS served as controls. Cells were washed twice in PBS, harvested by trypsination using 0.5% trypsin-0.2% EDTA, resuspended in 200 µl culture medium and counted by a Casy® TT cell counter according to the manufacturer's instructions (Schärfe System, Reutlingen, Germany). Cell count analyses were performed in quadruplicate with $n = 3$ separate cell preparations, respectively.

Determination of Cell Proliferation

Serum-starved PSCs (~80% density) were left untreated or treated with 10% FCS in the presence of CORM-2 at the indicated concentrations. Cell proliferation was evaluated with a BrdU-based enzyme-linked immunosorbent assay (Roche Diagnostics, Mannheim, Germany) according to the manufacturer's instructions. After 30 min incubation with the indicated substances, cells were labelled with BrdU for 20

hours at 37°C. Cells were fixed and incubated with a peroxidase-conjugated anti-BrdU antibody for 90 min at room temperature. After adding the peroxidase substrate 3,3´,5,5´-tetramethylbenzidine, BrdU incorporation was determined by measuring the optical densities at 370 nm minus the background at 492 nm. BrdU assays were performed in quadruplicate with at least $n = 3$ separate cell preparations, respectively.

Cell Cycle Analysis by Flow Cytometry

Culture-activated PSCs were starved from serum for 24 hours followed by a 24-h or 48-h stimulation with 10% FCS in the presence or absence of CORM-2 (100 µM). Cells were washed twice in PBS and harvested by trypsin digestion (0.5% trypsin-0.2% EDTA). Preparation of nuclei and propidium iodide staining was performed using a commercial kit (BD Biosciences, Heidelberg, Germany) according to the manufacturer´s recommendations and analysed on a FACS Calibur (BD Biosciences) using both CELLQuest® (BD Biosciences) and FlowJo® softwares (FlowJo, Ashland, OR, USA).

Western Blot Analysis

Total cell lysates were prepared by addition of 100 µl of RIPA buffer (50 mM Tris, pH 7.5, 150 mM NaCl, 1% Nonidet P40, 0.5% Sodium deoxycholat, 0.1% SDS). The protein content of the cell lysates was determined using a commercial protein assay kit (Thermo Fisher Scientific, Rockford, IL, USA). Equal amounts of proteins (40 µg) were separated on a 10% or 13% sodium dodecyl sulfate polyacrylamide gel. Proteins were transferred to a nitrocellulose membrane (Bio-Rad, Hercules, CA, USA), and the membranes were blocked with 5% skim milk in Tween-20/phosphate buffered saline and incubated with the indicated protein specific antibodies overnight at 4°C. After incubation with a horseradish peroxidase-conjugated anti-rabbit or anti-

mouse Ig antibody, proteins were visualized using the Enhanced Chemiluminescence Kit (GE Healthcare, Little Chalfont, Buckinghamshire, UK). For normalization, blots were reprobed with antibodies to detect total amounts of GAPDH, p38 MAPK, ERK1/2 or JNK. All blots were stripped and reprobed with an anti-GAPDH antibody to verify equal loading. Blots were analysed by laser scanning densitometry (Personal Densitometer, Molecular Dynamics, Krefeld, Germany). The results shown are representative of experiments with at least $n = 3$ different cell preparations.

siRNA Transfection

PSCs (1×10^5/ml) were transfected with 100 nM of a validated scrambled control siRNA (AllStars nonsilencing siRNA; QIAGEN GmbH, Hilden, Germany) or siRNA specifically targeting genes of interest, HO-1 (*hmox1_4* ['HO-1 siRNA A']; *hmox1_3* ['HO-1 siRNA B']; both obtained from QIAGEN GmbH) and p21$^{Waf1/Cip1}$ (Cdkn1a_2 ['p21 siRNA A']; Cdkn1a_3 ['p21 siRNA B']; Qiagen GmbH) using HiPerFect transfection reagent (QIAGEN GmbH) according to the manufacturer´s recommendations. Twelve hours after transfection, the medium was changed and PSCs were incubated in serum-free IMDM for 24 h before treatment.

Statistical Analysis

Results are expressed as means ± SEM for the indicated number of separate cell preparations per experimental protocol. Data were analyzed using one-way ANOVA followed by the Student-Newman-Keuls post-hoc test. Differences between groups were considered to be significant at $p < 0.05$. Analyses were performed using the SigmaStat® statistical software package (Systat Software GmbH, Erkrath, Germany).

RESULTS

CORM-2 Suppresses PSC Proliferation. To evaluate the effect of CORM-2 on PSC growth, cells were exposed to CORM-2 (12.5 - 100 μM) before stimulation with 10% FCS. Cell growth was determined by cell counts (Fig. 1A) and native microscopy (Fig. 1C). As shown in Fig. 1A, 10% FCS induced a profound increase in cell counts by 57% compared to cells incubated with 0.1% FCS. The administration of CORM-2 in 10% FCS stimulated cells caused a significant and dose-dependent decrease in cell numbers (129 ± 7.5% at 50 μM and 123 ± 3.7% at 100 μM), respectively. To further investigate the mechanism underlying the inhibitory effect of CORM-2 on PSC growth, cell proliferation in response to serum stimulation was assessed using BrdU incorporation assays. DNA synthesis in cells exposed to 0.1% FCS was defined as 100%. As shown in Fig. 1B, 10% FCS significantly stimulated PSC proliferation (154 ± 10.2%). Treatment of serum-stimulated cells with increasing amounts of CORM-2 (12.5 -100 μM) reduced BrdU incorporation in a dose-dependent manner. At higher concentrations, CORM-2 significantly and completely inhibited DNA synthesis (101 ± 4.8% at 50 μM and 89 ± 4.6% at 100 μM).

Cytotoxicity Profile of CORM-2 in PSCs. We then analysed whether the reduced cell growth following CORM-2 treatment was a consequence of necrosis or apoptosis. CORM-2 toxicity to culture-activated PSCs was investigated by examining LDH release. Tween-20 was added to the cell culture media to a final concentration of 1% for the determination of maximal LDH release (100%; Fig. 2A, grey bar). Compared with control (DMSO treatment only), CORM-2 did not cause a relevant increase in LDH release when used at concentrations between 12.5 and 100 μM. At higher concentrations, administration of CORM-2 results in a 10.4 ± 2.4% (200 μM), 13.7 ± 3.6% (500 μM), and 32.1 ± 4.2% (1000 μM) increase in LDH release (Fig. 2A).

On the basis of these observations, it was concluded that CORM-2 up to 100 µM was not toxic to cultured PSCs. We subsequently investigated whether CORM-2 induces apoptosis in PSCs by measuring the activity of caspase-3, a crucial enzyme in the induction of apoptosis, using a fluorogenic assay. Compared to control (DMSO), treatment of PSCs with the proapoptotic compound staurosporine (2 µM) led to a significant increase in caspase-3-like activity (Fig. 2B). In contrast, CORM-2 (12.5 – 1000 µM) had no effect.

CORM-2 Arrests PSCs at the G_0/G_1 Phase of the Cell Cycle. After synchronization by serum starvation for 24 h, PSCs were stimulated with 10% FCS in the presence or absence of CORM-2. Cells were stained with propidium iodide and cell cycle distribution was analyzed at 24 or 48 h after stimulation by flow cytometry. Compared to 10% FCS alone, CORM-2 decreased the percentage of cells in S and G_2/M phases by 41% (53.4 ± 4.3% versus 31.3 ± 2.1%) at 24 h and 55% (59.2 ± 6.2% versus 26.8 ± 3.7%) at 48 h (Fig. 3A+B).

CORM-2 Up-Regulates p21$^{Waf1/Cip1}$ and HO-1 Protein Expression in PSCs. To explore a possible mechanism that may account for the inhibitory effects of CORM-2 on cell cycle progression, the expression of p21$^{Waf1/Cip1}$, a potent inhibitor of G_1 cyclin-dependent kinases (Harper et al., 1993), was examined. As shown in Fig. 4A, CORM-2 significantly induced p21$^{Waf1/Cip1}$ expression compared to cells incubated with 10% FCS alone. Furthermore, we could show that treatment of PSCs with 10% FCS led to a slight increase in HO-1 protein expression, whereas CORM-2 profoundly up-regulated HO-1 (Fig. 4B).

CORM-2 Modulates MAPK Activation in PSCs. To elucidate the involvement of the MAPK pathways in the inhibitory effect of CORM-2 on PSC proliferation, serum-

starved PSCs were pre-incubated with CORM-2 for 30 min followed by a 4-h stimulation with 10% FCS. As demonstrated by Western blot analysis, 10% FCS caused a profound increase in phosphorylation of ERK1/2 (Fig. 5B) and JNK (Fig. 5C), whereas the level of phosphorylated p38 (Fig. 5A) was only slightly enhanced in presence of 10% FCS. The FCS-induced activation of ERK1/2 (Fig. 5B) or JNK (Fig. 5C) was not affected by CORM-2 treatment. In sharp contrast, CORM-2 led to a significant increase in p38 MAPK phosphorylation (Fig. 5A). Next we examined the effect of CORM-2 on MKK3 and MKK6, both of which have been shown to phosphorylate and activate p38 MAPK, but not ERK1/2 or JNK (Derijard et al., 1995; Raingeaud et al., 1996). As shown in Fig. 5D, 10% FCS alone had no effect on the level of phosphorylated MKK3/MKK6, whereas CORM-2 significantly induced phosphorylation of MKK3/6.

The role of p38 MAPK signaling in CORM-2 mediated effects. To assess the role of the p38 MAPK pathway on CORM-2 mediated effects, PSCs were pre-incubated with SB203580, a selective inhibitor of the p38α and –β isoforms (Cuenda et al., 1995), or with the inactive analog SB202474 before treatment with CORM-2. First we explored the effect of CORM-2, SB203580 and SB202474 treatment on the phosphorylation of MAPKAPK-2, a downstream target of p38 (Young et al., 1997). As shown in Fig. 6A, compared to the untreated control, 10% FCS alone had no effect on the level of phosphorylated MAPKAPK-2, whereas CORM-2 significantly induced phosphorylation of MAPKAPK-2. SB203580, but not SB202474, completely abrogated the CORM-2 induced increase in phosphorylated MAPKAPK-2. To investigate whether p38 MAPK activation confers to the inhibitory effect of CORM-2 on PSC proliferation, BrdU incorporation assays were performed. As shown in Fig. 6B, SB203580 treatment blocked the ability of CORM-2 to inhibit PSC proliferation,

whereas SB202474 had no effect. Finally we assessed the role of p38 signaling in CORM-2 induced p21$^{Waf1/Cip1}$ and HO-1 up-regulation. We found that co-administration of SB202474 did not prevent induction of p21$^{Waf1/Cip1}$ (Fig. 6C) or HO-1 (Fig. 6D). By contrast, SB203580 significantly attenuated the increase in both p21$^{Waf1/Cip1}$ and HO-1 protein following CORM-2 treatment.

HO-1 mediates the inhibitory effects of CORM-2 on PSC proliferation. To prove a causal relationship between CORM-2 induced HO-1 expression and the inhibitory effect of CORM-2 on PSC growth, cells were pre-treated with the HO inhibitor SnPP for 45 min before administration of CORM-2. As shown in Fig. 7, SnPP treatment alone had no effect on FCS-induced increase in PSC proliferation. In large contrast, the inhibitory effect of CORM-2 on PSC proliferation was significantly attenuated in presence of SnPP. To further explore whether CORM-2 suppresses PSC proliferation specifically via HO-1, we performed knock-down experiments by transfection of PSCs with two different HO-1 siRNAs. As indicated in Fig. 8A, transfection of nonsilencing siRNA had no effect on CORM-2-induced HO-1 up-regulation in FCS-stimulated PSCs. In absence of CORM-2, the level of HO-1 protein was comparable low in control-transfected and in anti-HO-1 siRNA transfected cells. By contrast, transfection with both anti-HO-1 siRNAs tested significantly attenuated CORM-2-induced up-regulation of HO-1 and reduced its inhibitory effect on PSC proliferation as demonstrated by BrdU proliferation assays (Fig. 8B).

Effect of HO-1 knock-down on CORM-2-induced p21$^{Waf1/Cip1}$ expression.
To clarify the role of HO-1 in CORM-2-induced p21$^{Waf1/Cip1}$ up-regulation, we examined the effect of HO-1 knock-down on p21$^{Waf1/Cip1}$ protein expression. We found that in control-transfected PSCs, CORM-2 strongly and significantly increased

the level of p21$^{Waf1/Cip1}$, whereas in cells transfected with different anti-HO-1 siRNAs the ability of CORM-2 to up-regulate p21$^{Waf1/Cip1}$ was significantly attenuated (Fig. 9).

Effect of p21$^{Waf1/Cip1}$ silencing on CORM-2 induced cell cycle arrest.

To determine whether a causal relationship exists between the ability of CORM-2 to up-regulate p21$^{Waf1/Cip1}$ and to induce G_0/G_1 cell cycle arrest, PSCs were transfected with different siRNAs to knock down p21$^{Waf1/Cip1}$ gene expression before exposure to CORM-2. Cell cycle analyses revealed that compared to cells transfected with control siRNA and treated with 10% FCS alone (Fig. 10A), transfection of p21 siRNA A (Fig. 10C) or p21 siRNA B (Fig. 10E) did not significantly alter the percentage of cell in S and G_2/M phases (50.7 ± 3.5% versus 51.9 ± 4.1% [p21 siRNA A] or 51.2 ± 3.9% [p21 siRNA B]). In line with previous data from our study, administration of CORM-2 decreased the percentage of non-silenced cells in S and G_2/M phases by 28% (Fig. 10B; 50.7 ± 3.5% versus 36.5 ± 2.9%). When cells were transfected with p21 siRNA A (Fig. 10D) or p21 siRNA B (Fig. 10F) prior to CORM-2 treatment, the ability of CORM-2 to induce G_0/G_1 cell cycle arrest was almost completely abrogated (Fig. 10G; 36.5 ± 2.9% versus 46.4 ± 3.6% [p21 siRNA A] or 45.7 ± 3.4% [p21 siRNA B]).

DISCUSSION

The present study demonstrates for the first time, that carbon monoxide releasing molecule-2 (CORM-2) inhibits PSC proliferation. This effect involves activation of p38 MAPK signaling, up-regulation of HO-1 protein, and p21$^{Waf1/Cip1}$-dependent cell cycle cycle arrest at the G_0/G_1 phase.

Carbon monoxide is increasingly recognized as a relevant mediator of numerous cellular functions (Ryter et al., 2006). It is generated endogenously during heme metabolism in a reaction catalyzed by HO enzymes. CO has been shown to exert anti-proliferative effects in smooth muscle cells (Song et al., 2002; Otterbein et al., 2003) and T lymphocytes (Song et al., 2004). In an experimental model of lung fibrosis, Zhou and colleagues have previously demonstrated that suppression of fibroblast proliferation contributes to the anti-fibrotic effects of CO (Zhou et al., 2005). To our knowledge, no such data are currently available concerning CO associated effects in the exocrine pancreas.

We have recently reported that HO-1 inhibits the proliferation of PSCs, a cell-type responsible for pancreatic fibrosis development (Schwer et al., 2008). In the present study, we investigated the effect of the HO-1 reaction product CO on PSC growth. Transition carbonyls acting as CO carriers could represent a way of supplying CO to tissues such as the pancreas in a more controllable fashion than achieved with CO gas, thereby reducing the risk of systemic toxicity (Motterlini et al., 2002; Sawle et al., 2006). We therefore used the carbon monoxide releasing compound CORM-2 to assess the effects of CO on PSC proliferation.

Using this approach we could demonstrate by BrdU assays and cell count analyses, that CORM-2 inhibits PSC proliferation. This effect was dose-dependent and significantly detectable starting at 50 µM. In addition, an increase in caspase-3-like activity could not be observed, suggesting that apoptosis is not involved in the

inhibitory effect of CORM-2 on PSC growth. It should be noted however, that the

concentrations of CORM-2 used in the present study are higher than those reported

to exert anti-proliferative effects in airway smooth muscle cells (Taille et al., 2005).

We assume that this discrepancy might reflect differences in the experimental design

including starving conditions or seeding densities of the two different cell types.

In an effort to understand possible mechanisms responsible for the inhibition of PSC

growth by CORM-2, we examined a possible effect on cell cycle progression. In

mammalian cells, proliferation is controlled primarily in the G_1-phase of the cell cycle

through the action of two cyclin-dependent kinases (Cdks), Cdk4 and Cdk2 (Koff et

al., 1992). These kinases are activated by association with cyclin E or cyclin D. The

activation of Cdk2 also requires dephosphorylation of Thr14 and Thr15 by Cdc25A

and an activating phosphorylation event at Thr160 by Cdk-activating kinase (CAK)

(Gu et al., 1992). Another mode of regulating Cdk2 kinase is through the association

with $p21^{Waf1/Cip1}$. $p21^{Waf1/Cip1}$ acts by binding to the cyclin E-Cdk2 complex and

inhibiting its kinase activity (Gu et al., 1993). Interestingly, Hitomi and collegues have

shown that $p21^{Waf1/Cip1}$ might function even more efficiently by binding to the cyclin-

Cdk complex prior to its activation in late G_1, and preventing the phosphorylation

event which is essential to its kinase activity (Hitomi et al., 1998). The results from

the current study indicate that CORM-2 arrests PSCs at the G_0/G_1 phase of the cell

cycle and this effect depends on up-regulation of $p21^{Waf1/Cip1}$ protein. These findings

are consistent with previous studies implying $p21^{Waf1/Cip1}$ as an important regulator of

PSC growth arrest (Manapov et al., 2005). Since we observed that CORM-2

prevented serum-induced phosphorylation of retinoblastoma tumor suppressor

protein (Rb) (data not shown), a downstream target of Cdk2, the inhibitory effect of

$p21^{Waf1/Cip1}$ on cell cycle progression could reflect a direct inhibition of cyclin E-Cdk2

kinase activity. However, it must be taken into consideration that the accessibility and cellular utilization of cyclin E-Cdk2 could also be targeted by CORM-2 treatment.

Many biological effects attributed to CO have been linked to its ability to modulate MAPK signaling pathways. MAPKs are activated by a wide range of extracellular stimuli and have been shown to play a pivotal role in the regulation of PSC growth (Jaster et al., 2002; Masamune et al., 2003). Previously, our laboratory has reported that HO-1 inhibits PSC proliferation by repression of the ERK1/2 pathway (Schwer et al., 2008). Effects of CO gas or CORMs on MAPK activation are variable and depend on the cell type. In airway smooth muscle cells and T cells, CO exerts its anti-proliferative effects via inhibition of ERK1/2 MAPK phosphorylation, while in vascular smooth muscle cells CO acts through activation of the p38 MAPK pathway (Wegiel et al., 2008). In the present study we found a marked activation of p38 MAPK following CORM-2 treatment, whereas an effect on ERK1/2 or JNK signaling could not be detected. The activation of p38 MAPK was associated with an activation of the upstream kinases MKK3/MKK6 and accompanied by the phosphorylation of a p38 target, MAPKAPK-2. SB203580, a pharmacological inhibitor of p38 MAPK, but not SB202474, an inactive analog, blocked the inhibitory effect of CORM-2 on PSC proliferation. These findings suggest that specific activation of the p38 MAPK cascade contributes to the CORM-2 induced cell growth arrest. In vascular smooth muscle cells, p38 MAPK signaling is involved in p21[Waf1/Cip1] induction (Lee et al., 2006). Since up-regulation of p21[Waf1/Cip1] was observed as the result of CORM-2 treatment, this prompted us to examine the role of p38 MAPK in the regulation of p21[Waf1/Cip1] expression in PSCs. SB203580 prevented CORM-2 induced p21[Waf1/Cip1] expression, indicating that CORM-2 up-regulates p21[Waf1/Cip1] via activation of p38 MAPK.

The critical role of p38 MAPK signaling in the regulation of HO-1 is well documented (Alam et al., 2000; Kietzmann et al., 2003). Recently, De Backer and colleagues have shown that CORMs could exert their effects via p38 dependent HO-1 induction in a mouse model of postoperative ileus (De Backer et al., 2008). However, inconsistent data exist about the ability of CORM-2 to up-regulate HO-1 (Sawle et al., 2005; Taille et al., 2005; Sun et al., 2008). In this respect, it was important to investigate whether CORM-2 induces HO-1 in PSCs. In the present study we could show a significant increase in HO-1 protein following CORM-2 treatment. These findings suggest that CORM-2 liberated CO might be responsible for HO-1 induction. Pharmacological p38 MAPK inhibition attenuated CORM-2 induced HO-1 up-regulation, indicating that HO-1 acts downstream of p38 in our experimental setting. In order to investigate whether HO-1 induction contributes to the protective effects of CORM-2, experiments with the pharmacological HO inhibitor SnPP and HO-1 siRNA were performed. In the presence of SnPP or by transfecting PSCs with HO-1 siRNA, CORM-2 failed to suppress PSC proliferation and up-regulate p21$^{\text{Cip1/WAF1}}$ protein. These data provide evidence for a causal involvement of HO-1 in the observed CORM-2 mediated inhibitory effects on PSC growth. Of note, HO-1 overexpression has been shown to up-regulate p21$^{\text{Waf1/Cip1}}$ in kidney proximal tubule cells (Inguaggiato et al., 2001). This observation would be in line with the data obtained in PSCs presented in this study.

On the basis of our current findings we conclude that CO released by CORM-2 exerts potent anti-proliferative effects in PSCs. Furthermore, CORM-2 inhibits PSC growth by a mechanism involving activation of p38 MAPK signaling and induction of HO-1 protein expression. The inhibitory effect of CORM-2 on PSC proliferation

appears to be linked to its ability to up-regulate p21$^{Waf1/Cip1}$. These findings suggest a

beneficial role of CORMs in the treatment of pancreatic fibrosis.

ACKNOWLEDGEMENTS

REFERENCES

Alam J, Wicks C, Stewart D, Gong P, Touchard C, Otterbein S, Choi AM, Burow ME and Tou J (2000) Mechanism of heme oxygenase-1 gene activation by cadmium in MCF-7 mammary epithelial cells. Role of p38 kinase and Nrf2 transcription factor. *J Biol Chem* **275**:27694-27702.

Apte MV, Haber PS, Applegate TL, Norton ID, McCaughan GW, Korsten MA, Pirola RC and Wilson JS (1998) Periacinar stellate shaped cells in rat pancreas: identification, isolation, and culture. *Gut* **43**:128-133.

Apte MV and Wilson JS (2004) Mechanisms of pancreatic fibrosis. *Dig Dis* **22**:273-279.

Bachem MG, Schneider E, Gross H, Weidenbach H, Schmid RM, Menke A, Siech M, Beger H, Grunert A and Adler G (1998) Identification, culture, and characterization of pancreatic stellate cells in rats and humans. *Gastroenterology* **115**:421-432.

Cuenda A, Rouse J, Doza YN, Meier R, Cohen P, Gallagher TF, Young PR and Lee JC (1995) SB 203580 is a specific inhibitor of a MAP kinase homologue which is stimulated by cellular stresses and interleukin-1. *FEBS Lett* **364**:229-233.

De Backer O, Elinck E, Blanckaert B, Leybaert L, Motterlini R and Lefebvre RA (2008) Water-soluble CO-releasing molecules (CO-RMs) reduce the development of postoperative ileus via modulation of MAPK/HO-1 signaling and reduction of oxidative stress. *Gut* **58**:347-356.

Derijard B, Raingeaud J, Barrett T, Wu IH, Han J, Ulevitch RJ and Davis RJ (1995) Independent human MAP-kinase signal transduction pathways defined by MEK and MKK isoforms. *Science* **267**:682-685.

Friedman SL (1993) Seminars in medicine of the Beth Israel Hospital, Boston. The cellular basis of hepatic fibrosis. Mechanisms and treatment strategies. *N Engl J Med* **328**:1828-1835.

Gu Y, Rosenblatt J and Morgan DO (1992) Cell cycle regulation of CDK2 activity by phosphorylation of Thr160 and Tyr15. *Embo J* **11**:3995-4005.

Gu Y, Turck CW and Morgan DO (1993) Inhibition of CDK2 activity in vivo by an associated 20K regulatory subunit. *Nature* **366**:707-710.

Haber PS, Keogh GW, Apte MV, Moran CS, Stewart NL, Crawford DH, Pirola RC, McCaughan GW, Ramm GA and Wilson JS (1999) Activation of pancreatic stellate cells in human and experimental pancreatic fibrosis. *Am J Pathol* **155**:1087-1095.

Harper JW, Adami GR, Wei N, Keyomarsi K and Elledge SJ (1993) The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases. *Cell* **75**:805-816.

Hitomi M, Shu J, Agarwal M, Agarwal A and Stacey DW (1998) p21Waf1 inhibits the activity of cyclin dependent kinase 2 by preventing its activating phosphorylation. *Oncogene* **17**:959-969.

Inguaggiato P, Gonzalez-Michaca L, Croatt AJ, Haggard JJ, Alam J and Nath KA (2001) Cellular overexpression of heme oxygenase-1 up-regulates p21 and confers resistance to apoptosis. *Kidney Int* **60**:2181-2191.

Jaster R, Sparmann G, Emmrich J and Liebe S (2002) Extracellular signal regulated kinases are key mediators of mitogenic signals in rat pancreatic stellate cells. *Gut* **51**:579-584.

Kietzmann T, Samoylenko A and Immenschuh S (2003) Transcriptional regulation of heme oxygenase-1 gene expression by MAP kinases of the JNK and p38

pathways in primary cultures of rat hepatocytes. *J Biol Chem* **278**:17927-17936.

Koff A, Giordano A, Desai D, Yamashita K, Harper JW, Elledge S, Nishimoto T, Morgan DO, Franza BR and Roberts JM (1992) Formation and activation of a cyclin E-cdk2 complex during the G1 phase of the human cell cycle. *Science* **257**:1689-1694.

Lee B, Kim CH and Moon SK (2006) Honokiol causes the p21WAF1-mediated G(1)-phase arrest of the cell cycle through inducing p38 mitogen activated protein kinase in vascular smooth muscle cells. *FEBS Lett* **580**:5177-5184.

Maines MD (1997) The heme oxygenase system: a regulator of second messenger gases. *Annu Rev Pharmacol Toxicol* **37**:517-554.

Manapov F, Muller P and Rychly J (2005) Translocation of p21(Cip1/WAF1) from the nucleus to the cytoplasm correlates with pancreatic myofibroblast to fibroblast cell conversion. *Gut* **54**:814-822.

Masamune A, Satoh M, Kikuta K, Sakai Y, Satoh A and Shimosegawa T (2003) Inhibition of p38 mitogen-activated protein kinase blocks activation of rat pancreatic stellate cells. *J Pharmacol Exp Ther* **304**:8-14.

Motterlini R, Clark JE, Foresti R, Sarathchandra P, Mann BE and Green CJ (2002) Carbon monoxide-releasing molecules: characterization of biochemical and vascular activities. *Circ Res* **90**:E17-24.

Omary MB, Lugea A, Lowe AW and Pandol SJ (2007) The pancreatic stellate cell: a star on the rise in pancreatic diseases. *J Clin Invest* **117**:50-59.

Otterbein LE, Zuckerbraun BS, Haga M, Liu F, Song R, Usheva A, Stachulak C, Bodyak N, Smith RN, Csizmadia E, Tyagi S, Akamatsu Y, Flavell RJ, Billiar TR, Tzeng E, Bach FH, Choi AM and Soares MP (2003) Carbon monoxide

suppresses arteriosclerotic lesions associated with chronic graft rejection and with balloon injury. *Nat Med* **9**:183-190.

Raingeaud J, Whitmarsh AJ, Barrett T, Derijard B and Davis RJ (1996) MKK3- and MKK6-regulated gene expression is mediated by the p38 mitogen-activated protein kinase signal transduction pathway. *Mol Cell Biol* **16**:1247-1255.

Ryter SW, Alam J and Choi AM (2006) Heme oxygenase-1/carbon monoxide: from basic science to therapeutic applications. *Physiol Rev* **86**:583-650.

Sawle P, Foresti R, Mann BE, Johnson TR, Green CJ and Motterlini R (2005) Carbon monoxide-releasing molecules (CO-RMs) attenuate the inflammatory response elicited by lipopolysaccharide in RAW264.7 murine macrophages. *Br J Pharmacol* **145**:800-810.

Sawle P, Hammad J, Fairlamb IJ, Moulton B, O'Brien CT, Lynam JM, Duhme-Klair AK, Foresti R and Motterlini R (2006) Bioactive properties of iron-containing carbon monoxide-releasing molecules. *J Pharmacol Exp Ther* **318**:403-410.

Schwer CI, Guerrero AM, Humar M, Roesslein M, Goebel U, Stoll P, Geiger KK, Pannen BH, Hoetzel A and Schmidt R (2008) Heme oxygenase-1 inhibits the proliferation of pancreatic stellate cells by repression of the extracellular signal-regulated kinase1/2 pathway. *J Pharmacol Exp Ther* **327**:863-871.

Song R, Mahidhara RS, Liu F, Ning W, Otterbein LE and Choi AM (2002) Carbon monoxide inhibits human airway smooth muscle cell proliferation via mitogen-activated protein kinase pathway. *Am J Respir Cell Mol Biol* **27**:603-610.

Song R, Mahidhara RS, Zhou Z, Hoffman RA, Seol DW, Flavell RA, Billiar TR, Otterbein LE and Choi AM (2004) Carbon monoxide inhibits T lymphocyte proliferation via caspase-dependent pathway. *J Immunol* **172**:1220-1226.

Sun B, Sun Z, Jin Q and Chen X (2008) CO-releasing molecules (CORM-2)-liberated CO attenuates leukocytes infiltration in the renal tissue of thermally injured mice. *Int J Biol Sci* **4**:176-183.

Taille C, El-Benna J, Lanone S, Boczkowski J and Motterlini R (2005) Mitochondrial respiratory chain and NAD(P)H oxidase are targets for the antiproliferative effect of carbon monoxide in human airway smooth muscle. *J Biol Chem* **280**:25350-25360.

Tenhunen R, Marver HS and Schmid R (1968) The enzymatic conversion of heme to bilirubin by microsomal heme oxygenase. *Proc Natl Acad Sci U S A* **61**:748-755.

Wegiel B, Chin BY and Otterbein LE (2008) Inhale to survive, cycle or die? Carbon monoxide and cellular proliferation. *Cell Cycle* **7**:1379-1384.

Witt H, Apte MV, Keim V and Wilson JS (2007) Chronic pancreatitis: challenges and advances in pathogenesis, genetics, diagnosis, and therapy. *Gastroenterology* **132**:1557-1573.

Young PR, McLaughlin MM, Kumar S, Kassis S, Doyle ML, McNulty D, Gallagher TF, Fisher S, McDonnell PC, Carr SA, Huddleston MJ, Seibel G, Porter TG, Livi GP, Adams JL and Lee JC (1997) Pyridinyl imidazole inhibitors of p38 mitogen-activated protein kinase bind in the ATP site. *J Biol Chem* **272**:12116-12121.

Zheng L, Zhou Z, Lin L, Alber S, Watkins S, Kaminski N, Choi AM and Morse D (2008) Carbon Monoxide Modulates {alpha}-smooth Muscle Actin and Small Proline Rich-1a Expression in Fibrosis. *Am J Respir Cell Mol Biol* **41**:85-92.

Zhou Z, Song R, Fattman CL, Greenhill S, Alber S, Oury TD, Choi AM and Morse D (2005) Carbon monoxide suppresses bleomycin-induced lung fibrosis. *Am J Pathol* **166**:27-37.

LEGENDS FOR FIGURES

Figure 1

Effect of CORM-2 on PSC proliferation. Serum-starved PSCs were incubated with CORM-2 at the indicated concentrations for 30 min followed by a 24-h stimulation with 10% FCS. (A) Cell numbers were determined by a computer-equipped cell counter. (B) DNA synthesis was estimated by measuring the incorporation of BrdU into cellular DNA. Data are presented as mean ± SEM for n = 3 separate cell preparations. **$p < 0.01$ *versus* 0.1% FCS; [#]$p < 0.05$ *versus* 10% FCS; [##]$p < 0.01$ *versus* 10% FCS. (C) Native microscopy. Pictures were taken from random fields of vision (original magnification 10 x objective).

Figure 2

Effects of CORM-2 on LDH release and caspase-3-like activity in PSCs. (A) Percentage of LDH released from PSCs after a 24-h incubation with increasing amounts of CORM-2 (12.5 - 1000 µM). Data are expressed as a percentage of the total LDH released after treatment of cells with Tween-20 (1%). (B) Caspase-3-like activity was assessed using a fluorogenic caspase activity assay. The results were given in relative fluorescent units (RFU). Data are presented as mean ± SEM for n = 3 separate cell preparations. *$p < 0.05$ *versus* control (DMSO only); **$p < 0.01$ *versus* control; ***$p < 0.001$ *versus* control; '*n.s.*' not significant *versus* control.

Figure 3

Effect of CORM-2 on cell cycle distribution. (A) Serum-starved PSCs were stimulated with 10% FCS for 24 h or 48 h in the presence or absence of CORM-2 (100 µM). Cells were harvested and cell cycle distribution was analyzed by flow cytometry. (B) Quantitative analysis of cells at S-G_2/M phase. Percentage of cells in S-G_2/M phase

obtained by flow cytometry. Data are presented as mean ± SEM for $n = 3$ separate cell preparations. $*p < 0.05$ *versus* 10% FCS; $**p < 0.01$ *versus* 10% FCS.

Figure 4

Effect of CORM-2 on $p21^{Waf1/Cip1}$ and HO-1 expression in PSCs. Serum-starved PSCs were incubated with CORM-2 (100 µM) for 30 min followed by a stimulation with 10% FCS for 24 h. $p21^{Waf1/Cip1}$ (A) and HO-1 (B) protein expression were determined by Western blot analysis. To show equal loading, the membranes were stripped and reprobed with an anti-GAPDH protein-specific antibody. The histograms represent the ratios between $p21^{Waf1/Cip1}$ or HO-1 optical densities and that of GAPDH. Data are presented as mean ± S.E.M. ($n = 3$). $*p < 0.05$ *versus* 0.1% FCS; $^{##}p < 0.01$ *versus* 10% FCS.

Figure 5

Effect of CORM-2 on MAPK activation and MKK3/MKK6 phosphorylation in PSCs. Serum-starved PSCs were pre-treated with CORM-2 (100 µM) for 30 min followed by a 4-h stimulation with 10% FCS. Phospho-p38 (P-p38; A), phospho-ERK1/2 (P-ERK1/2; B), phospho-JNK (P-JNK; C) and phospho-MKK3/MKK6 (P-MKK3/6; D) MAPK levels were determined by Western blot analysis using protein specific antibodies. The membranes were stripped and reprobed with anti-total-p38, anti-total-ERK1/2, anti-total-JNK and anti-total-MKK3/MKK6 antibodies. The histograms represent the ratios between phosphorylated MAPKs optical densities and that of their nonphosphorylated isoforms. Data are presented as mean ± S.E.M. ($n = 3$). $*p < 0.05$ *versus* 0.1% FCS; $**p < 0.01$ *versus* 0.1% FCS; $***p < 0.001$ *versus* 0.1% FCS; $^{##}p < 0.01$ *versus* 10% FCS; '*n.s.*' not significant *versus* 10% FCS.

Figure 6

Role of p38 MAPK inhibition on CORM-2 mediated effects on PSC proliferation, p21$^{Waf1/Cip1}$ and HO-1 expression. Serum-starved PSCs were pre-treated with SB203580 (10 µM) or SB202474 (10 µM) for 30 min before exposure to CORM-2 (100 µM). (A) Representative Western blot analysis of phospho-MAPKAPK-2 (P-MAPKAPK-2) expression after an 8-h stimulation with 10% FCS. The graph shows the ratios between phospho-MAPKAPK-2 (P-MAPKAPK-2) optical densities and that of GAPDH (n = 3). (B) Cell proliferation as assessed by BrdU assays after a 24-h incubation with 10% FCS. The results are expressed as a percentage of the untreated control (n=4). (C) Western blot analysis of p21$^{Waf1/Cip1}$ and (D) HO-1 protein expression. Whole cell proteins were extracted from PSCs after a 24-h stimulation with 10% FCS. To demonstrate equal loading, the membranes were stripped and reprobed with an antibody against GAPDH. The histograms represent the ratios between p21$^{Waf1/Cip1}$ or HO-1 optical densities and that of GAPDH. The data are presented as mean ± SEM (n=3). *$p < 0.05$ *versus* 0.1% FCS; ***$p < 0.001$ *versus* 0.1% FCS; #$p < 0.05$ *versus* 10% FCS; ##$p < 0.01$ *versus* 10% FCS; ###$p < 0.001$ *versus* 10% FCS; &$p < 0.05$ *versus* 10% FCS + CORM-2; &&$p < 0.01$ *versus* 10% FCS + CORM-2; '*n.s.*' not significant *versus* 10% FCS + CORM-2.

Figure 7

Effect of CORM-2 and/or SnPP on FCS-induced PSC proliferation. Serum-starved PSCs were pre-incubated with SnPP (20 µM) for 45 min before exposure to CORM-2 (100 µM). Cells were stimulated to proliferate with 10% FCS and DNA synthesis was estimated by measuring the incorporation of BrdU into cellular DNA. Results are expressed as percentage of control values observed in PSCs not incubated with 10% FCS. Data are presented as mean ± SEM for n=3 separate cell preparations. ***$p <$

0.001 *versus* 0.1% FCS; [##]$p < 0.01$ *versus* 10% FCS; [&&]$p < 0.01$ *versus* 10% FCS + CORM-2.

Figure 8

Role of HO-1 in the inhibitory effect of CORM-2 on PSC proliferation. PSCs were transfected with siRNAs directed against hmox1-mRNA (HO-1 siRNA A, HO-1 siRNA B) or nonsilencing siRNA not targeting any gene product (Control siRNA). After transfection, cells were incubated in serum-free medium for 24 h. CORM-2 (100 μM) was added to the cells for 30 min followed by a 24-h stimulation with 10% FCS. (A) HO-1 protein expression was assessed by Western blot analysis. The membrane was striped and reprobed with an anti-GAPDH protein specific antibody. The histogram represents the ratios between HO-1 optical densities and that of GAPDH. (B) DNA synthesis was estimated by measuring the incorporation of BrdU into cellular DNA. Data are presented as mean ± SEM ($n = 3$). [*]$p < 0.05$ *versus* 0.1% FCS; [***]$p < 0.001$ *versus* 0.1% FCS; [##]$p < 0.01$ *versus* 10% FCS + Control siRNA; [&]$p < 0.05$ *versus* 10% FCS + CORM-2 + Control siRNA; [&&]$p < 0.01$ *versus* 10% FCS + CORM-2 + Control siRNA; '*n.s.*' not significant *versus* 10% FCS + Control siRNA.

Figure 9

Role of HO-1 on CORM-2-induced p21$^{Waf1/Cip1}$ expression. PSCs were transfected with siRNAs directed against hmox1-mRNA (HO-1 siRNA A, HO-1 siRNA B) or nonsilencing siRNA (Control siRNA) before addition of CORM-2 (100 μM) for 24 h. The level of p21$^{Waf1/Cip1}$ protein was examined by Western blot analysis. The graph shown represents the optical density ratios of p21$^{Waf1/Cip1}$ and GAPDH. Data are presented as mean ± SEM ($n = 3$). [##]$p < 0.01$ *versus* 10% FCS + Control siRNA; [&]$p < 0.05$ *versus* 10% FCS + CORM-2 + Control siRNA.

Figure 10

Role of $p21^{Waf1/Cip1}$ in CORM-2-induced G_0/G_1 cell cycle arrest. (A) PSCs were transfected with siRNAs directed against $p21^{Waf1/Cip1}$-mRNA (p21 siRNA A, p21 siRNA B) or nonsilencing siRNA (Control siRNA) followed by a 24-h starvation from serum. Cells were stimulated with 10% FCS in the presence or absence of CORM-2 (100 μM) and cell cycle distribution at 24 h was analyzed by flow cytometry. (B) Quantitative analysis of cells at S-G_2/M phase. Percentage of cells in S-G_2/M phase obtained by flow cytometry. Data are presented as mean ± SEM for $n = 3$ separate cell preparations. *$p < 0.05$ *versus* 10% FCS + Control siRNA; '*n.s.*' not significant *versus* 10% FCS + Control siRNA; #$p < 0.05$ *versus* 10% FCS + CORM-2 + Control siRNA.

A

B

C

Figure 1

A

B

Figure 2

Figure 3

A

B

Figure 4

Figure 5

A

B

Figure 6

C

D

Figure 6

Figure 7

Figure 8

Figure 9

A

10% FCS + Control siRNA

B

10% FCS + Control siRNA + CORM-2

C

10% FCS + p21 siRNA A

D

10% FCS + p21 siRNA A + CORM-2

E

10% FCS + p21 siRNA B

F

10% FCS + p21 siRNA B + CORM-2

Figure 10

G

Figure 10